Catalog No.
KDD03401
Description
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human MIF has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Imalumab in the sample competitively binds to the pre-coated protein with biotin-labeled Imalumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Imalumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Imalumab concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
234.38 - 15,000 ng/mL
Sensitivity
158.16 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision |
Inter-Assay Precision |
||||
|
Sample |
1 |
2 |
3 |
1 |
2 |
3 |
|
n |
16 |
16 |
16 |
24 |
24 |
24 |
|
Mean (ng/mL) |
8157.6 |
2541.5 |
524.6 |
8362.2 |
2540.8 |
479.5 |
|
Standard deviation |
1206.3 |
389.4 |
73.9 |
1063.6 |
404.9 |
74.3 |
|
CV (%) |
14.8 |
15.3 |
14.1 |
12.7 |
15.9 |
15.5 |
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Alternative Names
BAX069, BAX69, CAS: 1430205-07-4
Background
Imalumab (as known as Bax69) is a novel recombinant, fully-human, monoclonal antibody (mAb) which was designed and developed to target the macrophage migration inhibitory factor, with potential immunomodulating, anti-inflammatory and antineoplastic activities. This drug was developed by Cytokine Pharma Sciences and Baxalta, which was purchased by Shire Pharmaceuticals. Phase I studies were completed in early 2016 and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer. However, it is disappointing that there are no breakthrough and exciting clinical trial results for this monoclonal antibody. For example, a phase I/II trial in patients with malignant ascites was terminated in 2016 and Baxalta terminated a phase II trial in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA, Spain on 02 Jun 2017.
For research use only. Not for human or drug use.
